Inhibition of HER2-integrin signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression

HER2, an oncogenic receptor is overexpressed in about 25-30% of breast cancer patients. HER2 has been shown to play role in tumor promotion by having cross-talk with multiple oncogenic pathways in cancer cells. Our results show that Cucurbitacin B (CuB), a triterpenoid steroidal compound inhibited t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Parul, Srivastava, Sanjay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039119/
https://www.ncbi.nlm.nih.gov/pubmed/24729020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039119/
https://www.ncbi.nlm.nih.gov/pubmed/24729020

Ejemplares similares